Micic, S. (7006493137)S. (7006493137)MicicBila, S. (7004379936)S. (7004379936)BilaIlic, V. (7006666131)V. (7006666131)IlicSulovic, V. (7006602555)V. (7006602555)Sulovic2025-06-122025-06-121985https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021850158&partnerID=40&md5=324616ad80378338f398f071b99cd9abhttps://remedy.med.bg.ac.rs/handle/123456789/2080A randomised group of 75 men with idiopathic oligoasthenozoospermia and asthenozoospermia were subjected to a control study with kallikrein. Kallikrein was given to 45 men, 600 units daily in a period of 3-6 months. The other group of 30 infertile men was followed during the same period of time. Percentage of motile sperm was significantly improved after 3-6 months' treatment with kallikrein. Sperm count and percentage of morphologically normal sperm showed improvement but this was not statistically significant. Infertile men with a sperm count below 20 x 106/ml had greater improvement in sperm count than men with a sperm count over 20 x 106/ml. This study emphasizes that kallikrein is a relatively good drug for restoring sperm motility in idiopathic oligoasthenozoospermia and asthenozoospermia.